FDA approves Merck RSV Baby Shot for Sanofi Astrazeneca rival

Food and Medicines Administration on Monday approved Merk ‘S Shot designed to protecting babies From the respiratory syncytial virus during their first season of the virus, by applying a rival to such treatment by Sanofi and AstrazenecaS

Thehe decision It will allow the company to release the medicine, which will be available on the market like Enflonsia, before the RSV season, which usually starts around the fall and winter and continues in the spring. Merk said in a announcement that he expects to be ordered for the shot to start in July, with deliveries delivered before the virus begins to spread widely.

Approval gives doctors a new option for dealing with the virus, which causes thousands of deaths among older Americans and hundreds of deaths among babies each year. Complications of RSV are the leading cause of hospitalization among newborns.

“We are committed to guaranteeing the availability of (Enflons) in the United States before the start of the upcoming RSV season to help reduce the significant severity of this widespread seasonal infection of families and health systems,” says D -R Dean, President of Merck Research Laboratories.

Merk’s shot will compete against a similar treatment of the Sanofi and Astrazeneca blockbuster, called Beyfortus, which is deficient across the country in 2023. The RSV seasons due to unprecedented demand.

Both are preventive monoclonal antibodies that supply antibodies directly to the blood to provide immediate protection. But everyone is directed to another part of the virus, which makes it difficult to compare them directly.

The Merck shot can be administered to babies, regardless of their weight that the company said it could offer dosage convenience. Meanwhile, the recommended dose of Beyfortus is based on the baby’s body weight.

Sanofi on Monday discovered Aggressive effort to increase the delivery of Beyfortus, including a plan to start the delivery of the shot at the beginning of the third quarter. Last year, Beyfortus booked sales of 1.7 billion euros ($ 1.8 billion).

RSV vaccines are also available in the United States by companies such as Pfizer., GSK and ModernS But these photos are only for use in adults or in pregnant women. FDA recently Pause testing of RSV photos in young children while evaluating safety concerns.

All market companies are waiting for a meeting of external vaccine advisers at the Centers for the Control and Prevention of Diseases from June 25 to 27, when they will form recommendations for RSV photos and other immunizations.

In the medium to late ENFLONSIA test, the shot reduced RSV-related hospitalizations by over 84% and reduced hospitalizations due to lower respiratory infections by 90% compared to placebo among babies over five months. The shot also reduced infections with a smaller breath, requiring medical attention by more than 60% compared to placebo in five months.

RSV is a common cause of lower respiratory tract infections such as pneumonia.